0.00Open2.30Pre Close0 Volume155 Open Interest190.00Strike Price0.00Turnover129.17%IV19.88%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry2.30Extrinsic Value100Contract SizeAmericanOptions Type-0.1050Delta0.0043Gamma101.86Leverage Ratio-0.5282Theta-0.0050Rho-10.70Eff Leverage0.0596Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet